JPRN-jRCT2011200003进行中（未招募）3 期
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects with Late onset Pompe Disease
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Subject must have completed Study ATB200-03
排除标准
- •1. Subject plans to receive gene therapy or participate in another interventional study for Pompe disease.
- •2. Subject, if female, is pregnant or breastfeeding.
- •3. Subject, whether male or female, is planning to conceive a child during the study.
研究者
相似试验
进行中（未招募）
1 期
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe diseaseAdult Subjects With Late Onset Pompe Disease (LOPD)MedDRA version: 24.0Level: LLTClassification code 10075702Term: Pompe's disease late onsetSystem Organ Class: 100000004850EUCTR2019-000954-67-ITAMICUS THERAPEUTICS, INC.120
招募中
3 期
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe DiseaseGlycogen storage disease type II10028396Pompe diseaseNL-OMON54552Amicus Therapeutics1
进行中（未招募）
1 期
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe diseaseEUCTR2019-000954-67-GBAmicus Therapeutics, Inc.110
进行中（未招募）
1 期
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe diseaseAdult Subjects With Late Onset Pompe Disease (LOPD)MedDRA version: 24.0Level: LLTClassification code 10075702Term: Pompe's disease late onsetSystem Organ Class: 100000004850EUCTR2019-000954-67-BEAmicus Therapeutics, Inc.110
进行中（未招募）
1 期
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe diseaseEUCTR2019-000954-67-GRAmicus Therapeutics, Inc.110